|
|
Line 26: |
Line 26: |
| * New research on the relative safety of American dip/chew products indicates that smokeless users who had never smoked showed no significant risks for numerous diseases. | | * New research on the relative safety of American dip/chew products indicates that smokeless users who had never smoked showed no significant risks for numerous diseases. |
| * In summary, American dip/chew and Swedish snus are indistinguishable with respect to health impact. Smokers who switch to any of these products can make smoking history. | | * In summary, American dip/chew and Swedish snus are indistinguishable with respect to health impact. Smokers who switch to any of these products can make smoking history. |
| | In a press release 16 March 2023 [https://www.fda.gov/news-events/press-announcements/fda-authorizes-copenhagen-classic-snuff-be-marketed-modified-risk-tobacco-product FDA Authorizes Copenhagen Classic Snuff to be Marketed as a Modified Risk Tobacco Product] |
|
| |
|
| Please note that other products listed in the table below may be significantly more risky, information on the relative risks and those compared to smoking are not easily available. | | * FDA authorized U.S. Smokeless Tobacco Company (USSTC) to market its Copenhagen Classic Snuff, a loose moist smokeless tobacco product, as a modified risk tobacco product (MRTP). |
| | * This product is a pre-existing tobacco product that has been marketed in the U.S. for years without modified risk information. |
| | * This action now allows the product to be marketed as a modified risk tobacco product with the claim: “IF YOU SMOKE, CONSIDER THIS: Switching completely to this product from cigarettes reduces risk of lung cancer.” |
| | |
| | Please note that other products listed in the table below may be significantly more risky, information on the relative risks and those compared to smoking are not easily available. |
|
| |
|
| ==== Possible advantages ==== | | ==== Possible advantages ==== |